2

- Kimberly Peven, PhD² 3
- Ryan Bamford, MSc² 4
- 5 Liudmila Zhaunova, PhD²
- Rodion Salimgaraev, MD² 6
- Carley Prentice, BA² 7
- 8 Aidan Wickham, PhD²
- Jazz Croft, PhD² 9
- Sonia Ponzo, PhD^{2, 3} 10
- Samir Babayev, MD¹ 11
- ¹ Department of Obstetrics and Gynecology, Division of Reproductive Endocrinology and 12
- 13 Infertility, Mayo Clinic, Rochester, Minnesota
- ² Flo Health UK Limited, London, United Kingdom 14
- 15 ³ University College London, Institute of Health Informatics
- Address Correspondence to: Samir Babayev, MD 17
- Mayo Clinic 18
- 200 First Street SW 19
- 20 Rochester, MN 55905
- 21 (507) 284-2511
- Babayev.samir@mayo.edu 22
- Short Title: Global Menstrual Symptoms 23

Financial Disclosure: Kimberly Peven: Flo Health UK Limited (Employment), Ryan Bamford:

Flo Health UK Limited (Employment), Liudmila Zhaunova: Flo Health UK Limited
(Employment, ownership interest includes stock, stock options), Rodion Salimgaraev: Flo
Health UK Limited (Employment, ownership interest includes stock, stock options), Carley
Prentice: Flo Health UK Limited (Employment), Aidan Wickham: Flo Health UK Limited
(Employment), Jazz Croft: Flo Health UK Limited (Employment), Sonia Ponzo: Flo Health UK
Limited (Employment, ownership interest includes stock, stock options). Other authors did not report any potential conflicts of interest.

33	Title: Global Menstrual Cycle Symptomatology
34	
35	Precis: Menstrual symptoms include both positive and negative physical and mood symptoms
36	and differ by age.

Abstract **Objective**: To investigate symptomatology throughout the menstrual cycle, including the frequency of symptoms reported for each phase of the cycle and the relationship between symptoms and individual characteristics. **Methods**: This study included self-reported cycle information and symptoms during ovulatory menstrual cycles in mobile application users. Symptom frequency was described overall, by phase, and by day. Relationships between symptoms and individual characteristics (age, body mass index) were tested with logistic regression. **Results**: 224,676 unique users and 498,126 unique cycles were included in the analysis. Somatic symptoms were most frequently reported, logged in 85.3% of cycles. Of total symptoms logged, somatic, gastrointestinal, and negative mood symptoms were most prevalent in the late luteal and bleeding days, while positive mood and discharge were most common in the fertile window. Symptom experience differed by age. **Conclusions**: Menstrual cycle-related symptoms are very common and vary throughout the cycle phases. While most women report negative symptoms including pain, bloating, and negative mood, women also report positive symptoms such as energetic and happy mood. Self-reported data from cycle tracking and health apps can improve our understanding of the prevalence and variability of menstrual-related symptoms.

Funding Source: Flo Health UK Limited

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

Introduction:

58

59

60

61

62

63

64

65

66

67

68

69

70

71

72

73

74

75

76

77

78

79

80

Although a shared experience by women and people who menstruate throughout the world, menstruation represents an area of health often ignored and misunderstood by both patients and health care providers. While many individuals experience menstruation without significant symptoms, others endure pain and many other somatic, gastrointestinal, and mood symptoms which vary throughout the cycle. Dysmenorrhea affects 45-95% of menstruating individuals with wide variation due to differing definitions of the condition¹. Compared with pain-free phases of their cycles, those suffering from dysmenorrhea experience reduced quality of life, poor mood, and decreased sleep during menstruation¹. Gastrointestinal symptoms also vary throughout the menstrual cycle, with one-third of women experiencing symptoms during menstruation^{2,3}. Additionally, irritability and mood swings can affect 22-40% of women, more often before menstruation⁴. As it relates to symptom co-occurrence, individuals with mood symptoms like depression and anxiety are more likely to experience multiple gastrointestinal symptoms both before and during menstruation⁵. Despite improved standardization in terminology and increasing prioritization of women's health issues, these symptoms are underreported⁶⁻⁸. Importantly, menstrual symptoms may present a significant impairment to productivity and quality of life⁹.

A recent review highlighted challenges in the field of menstrual health research¹⁰. These challenges include how and from whom data is collected, the impact of normalization of symptoms and stigma regarding menstrual disorders, lack of standardized assessment tools, and differing cultural perceptions of this physiologic process^{10–13}. Previous studies of symptom prevalence and variation throughout the menstrual cycle have included surveys based on recall or small prospective studies^{4,5}. Multiple approaches to improve our understanding of patient

symptoms and population norms of menstrual cycle symptoms, both normal and abnormal, are required to best address current gaps in knowledge. The emerging availability of mobile applications (apps) and user-reported data is one such approach that allows for 'digital epidemiology' $^{14-16}$. For example, reported cycle characteristics of more than 600,000 menstrual cycles recorded by a mobile app found a mean luteal phase length of 12.4 ± 2 days¹⁷. This data represents population norms and differs from the classical teaching of a conserved 14-day luteal phase¹⁷.

In this study, through app user-reported data, we aim to report a population-based assessment of symptomatology throughout the menstrual cycle. Specific objectives include describing the frequency of symptoms reported in each phase of the menstrual cycle and evaluation of how symptoms may be associated with personal characteristics.

Methods:

This cohort study includes active users of the Flo app between January 1, 2018, and April 1, 2022. Users aged 18-45, not pregnant, and actively involved in the app (reporting at least six menstrual cycles) were included. Menstrual cycles between 21-40 days, menstrual bleeding between 1-10 days, follicular and luteal phase lengths of at least five days each, and positive ovulation predictor kit use were used to define 'normal' menstrual cycles.

Cycle dates and phases were calculated based user provided data. The start of a new menstrual cycle was defined as the first day of bleeding. Mid-follicular phase was defined as the day after the last day of menstrual bleeding until the start of the fertile window (Figure 1). An individual with less than five days between end of menstrual bleeding and day of ovulation had no defined mid-follicular phase. The fertile window was calculated as the five days preceding

the late luteal phase.

Symptoms were self-reported and associated with the phase of the menstrual cycle as defined above. We classified symptoms into five groups: somatic (cramps, tender breasts, headache, fatigue, backache, acne), gastrointestinal (bloating, nausea, diarrhea, cravings, constipation), positive mood (happy, high sex drive, energetic), negative mood (mood swings, anxious, depressed, insomnia, stress, obsessive thoughts), and discharge (creamy, egg white, sticky, watery). Users could record as many symptoms in each category as desired each day.

Individual characteristics were matched to each cycle. Age at the time of the cycle was based on the user's birthdate and cycle dates. Height and weight were optionally entered into the app by users and used to calculate body mass index (BMI). A user's country was assigned based on phone settings at app installation. Where country at app installation was unavailable, country phone settings at last login was used. Country prevalence of symptoms was evaluated only when 100 users or more were included.

Statistical Methods

Using a cycle-level unit of analysis, we employed descriptive statistics to describe cycle length and symptoms experienced overall and by phase. For cycles with a length of 25-30 days, we describe symptoms experienced by day of the cycle, where day 1 is the first day of bleeding. We fitted multivariable logistic regression models to explore the association between individual characteristics (age, BMI) and experience of menstrual symptoms. Menstrual symptoms were divided into categories (somatic, gastrointestinal, negative mood, and positive mood) and were

considered if any symptom in the category was logged at any point in the cycle. We categorized the age of study subjects into five groups (18-24, 25-29, 30-34, 35-39, and 40-45), where the most represented age category, age 30-34, was used as the reference group. BMI was categorized into four groups (<18.5, 18.5-24.9, 25-29.9, 30+). All models controlled for the total number of symptoms reported. Data were analyzed in Python Jupyter Notebook 6.0.1 and R version 4.2.0.

Results:

A total of 224,676 unique users and 498,126 unique, normal menstrual cycles met inclusion criteria and were included for analysis with a median and interquartile range (IQR) of the cycle length of 2.0 and 1.0, respectively, per individual. The mean age of users was 30.2 ± 5.7 years; users under age 18 or over 45 were excluded from the analysis. Mean BMI, available for 135,979 users (60.5% of total users) was 26.0 (13.5-58.3) kg/m². Users were included from 222 countries, with 93 countries having at least 100 users. The largest group of users was in the United States (n=73,015), followed by Germany (n=19,956) and the United Kingdom (n=17,437).

Of the 498,126 cycles included in this analysis, mean cycle length was 29.1 ± 3.4 days (median 28.8 days), and mean length of bleeding was 4.0 ± 1.2 days (median 4.0 days). Most users recorded a cycle length of 25-30 days (64.1%, n = 144,148), followed by cycle length of 31-34 days (20.5%, n=46,072), 35-40 days (8.0%, n=17,921), and 21-24 (7.3 %, n = 16,535). Calculated from the predicted day of ovulation, the mean follicular phase length amongst users was 15.6 ± 3.5 days (median 15.0 days), and the mean luteal phase length was 13.5 ± 2.8 days (median 13.4 days).

Somatic symptoms were reported most often; 85.3% (n=498,126) of cycles reported at least one somatic symptom. Comparatively, gastrointestinal symptoms were reported in 55.8% of

cycles (n=278,090), positive mood symptoms were reported in 24.1% (n=119,961) of cycles, and negative mood symptoms were reported in 31.6% (n=157,412). The type and frequency of symptoms are shown in Figure 2. Menstrual cramps, breast tenderness, headache, and fatigue were the most common symptoms reported.

Symptoms were next assessed by the menstrual cycle phase. Somatic, gastrointestinal, and negative mood symptoms were most frequent in the late luteal phase and least frequent in the mid-follicular phase (Figure 3). 54.5% of all logged instances of tender breasts occurred during the late luteal phase compared to 2.5% in the mid-follicular phase. Discharge and positive mood symptoms were most common during the fertile window. 68.1% of all logged instances of egg white discharge and 44.5% of all logged instances of high sex drive were during the fertile window.

For cycles between 25-30 days in length (n=294,180 cycles), we examined daily symptom logs for the three symptoms with the most variability per category (Figure 4). Overall, most symptoms are reported on day 1 of the cycle (238,391 symptoms logged from 110,206 cycles out of 294,180 total cycles); however, the fertile window is where most cycles have at least one symptom logged. Out of 294,180 total cycles, 210,910 cycles had at least one symptom logged during the fertile window, and 146,580 had at least one symptom logged during the bleeding days. The prevalence of somatic, gastrointestinal, and negative mood symptoms are highest on day 1 but decline quickly, reaching their lowest point around day 6 before slowly increasing throughout the rest of the cycle. For positive mood symptoms, the prevalence of energetic mood remains relatively stable throughout the cycle, while happy and high-sex-drive moods increase slowly in the early part of the cycle, peaking around day 13-14 of the cycle and reaching baseline around day 19. Discharge symptoms are rarely logged during the early part of

the cycle where bleeding occurs. Egg white discharge increases rapidly between days 6 and 13 before decreasing quickly to a low level by day 19.

For countries with at least 100 users, the number per country ranged from 104 in Zimbabwe to 73,015 in the United States (Supplemental Table 1). Prevalence of cramps during the last cycle ranged from 4.3% in Vietnam to 23.5% in Iceland (Figure 5). Bloating ranged from 1.7% in The Congo to 9.5% in Tunisia. Mood swings ranged from 0.8% in Iceland to 7.6% in Jamaica.

Younger users, aged 18-24, were more likely to report positive mood symptoms at any point in the cycle compared to women aged 30-34 (referent group) (OR 1.39, 95%CI: 1.33 - 1.46) and were also more likely to experience negative mood symptoms (OR: 1.38, 95%CI: 1.31 - 1.44). Younger women were less likely to report any somatic symptoms (OR 0.87, 95%CI: 0.81 - 0.93). Gastrointenstinal symptoms did not differ between young and referent aged women but were reported more frequently in users aged 40-45(OR 1.11, 95%CI: 1.04 - 1.19).

There was no significant association between BMI and experiencing either a somatic or negative mood symptom at any point across the cycle whilst controlling for age and total number of symptoms logged.

Discussion:

In this study, we report the frequency of somatic, gastrointestinal, mood, and discharge symptoms experienced throughout the menstrual cycle by a cohort of global, ovulating period tracking app users. Notably, most users were aged 30-34 and located in Europe and the United States. Our results build on prior work evaluating the menstrual cycle characteristics of women

using period tracking apps. The median cycle length, 28.7 days in our study, is consistent with previous studies and period tracking app data^{17,20–24}.

191

192

193

194

195

196

197

198

199

200

201

202

203

204

205

206

207

208

209

210

211

212

213

Somatic symptoms were reported most frequently, with cramps being the most reported symptom. Somatic, gastrointestinal, and negative mood symptoms were more common in the late luteal phase than in the rest of the cycle and reached a nadir in the mid-follicular phase between bleeding and the fertile window/ovulation. The hormonal changes observed in the luteal phase may explain these findings. There is a direct correlation between the rapid rise of progesterone, the dominant sex hormone in the luteal phase, and the abrupt increase in somatic symptoms. Progesterone has been shown to influence breast changes and associated breast tenderness in the luteal phase²⁵. By thermoregulatory actions, progesterone has also been shown to impact circadian rhythms leading to decreased REM sleep in the luteal phase and thus a reported increase in fatigue²⁶. However, progesterone levels fall in the week prior to menstruation while somatic symptoms continue to increase. Symptoms in the late luteal phase reflect the effect of decreasing systemic sex steroid hormones. Pain disorders, such as migraines and non-migraine headaches, have been shown to increase in the late luteal phase when estradiol levels are lowest^{27–29}, in line with our findings of headaches being most reported in this phase. These effects are modulated by estrogen effects on central pain processing networks and cerebral vasculature²⁸. Conversely, decreasing progesterone levels and the resultant increase in available androgen receptors may explain the increase in acne reported in the late luteal phase³⁰.

Gastrointestinal symptoms that increase throughout the luteal phase likely reflect multiple mechanisms³. First, the effect of progesterone on serotonergic activity in both the central nervous system and the GI tract slows gastrointestinal motility leading to constipation in the early luteal phase³¹. Second, increasing prostaglandin levels in the late luteal phase lead to stimulation of

smooth muscle contractions – leading to both uterine cramping and increased gastrointestinal motility and associated diarrhea³².

214

215

216

217

218

219

220

221

222

223

224

225

226

227

228

229

230

231

232

233

234

235

236

The effect of the menstrual cycle on mental health has been well studied, and premenstrual mood disorders are well classified, with over 300 subtypes reported. Mood changes in the luteal phase affect 50-80% of reproductive-aged women, although 3-8% of individuals have such severe symptoms with associated functional impairments that they meet diagnostic criteria in the DSM-IV³³. Our study confirmed an increase in negative mood symptoms throughout the luteal phase, possibly reflecting known alterations in sex steroids and the following neurotransmitters: serotonin, noradrenaline, and gamma-aminobutyric acid (GABA)^{33,34}. Negative mood symptoms decreased throughout the follicular phase, with a corresponding increase in positive mood symptoms that reached peak levels in the late follicular phase. Positive mood symptom frequency in the follicular phase is consistent with prior studies reporting individual well-being to be highest at this time in the cycle^{35,36}. Recent work utilizing functional magnetic resonance imaging (fMRI) has added to our understanding. Sex hormones appear to impact communication between brain regions, in addition to their known impact on neurotransmitter secretion³⁷. This impacts cognition and emotional processing, such that estrogen seems to decrease reaction to negative stimuli while progesterone seems to increase emotional reactions to negative stimuli³⁸.

Different menstrual symptom patterns by age have been described³⁹. While we found occurrence of somatic symptoms at any time during the cycle was lowest in the youngest and oldest age groups, premenstrual symptom research has found premenstrual cramps and abdominal pain decrease with age while other somatic premenstrual symptoms (e.g. back pain, abdominal bloating, breast tenderness) are lower in the youngest and oldest groups. The

relationship between BMI and menstrual symptoms in the literature is mixed. Some research suggests obesity may be a risk factor for premenstrual syndrome ^{40,41} while other research failed to find an association between BMI and premenstrual symptoms ⁴². Similarly, we found no relationship between BMI and somatic or negative mood symptoms.

We found small geographic differences in user-reported symptoms during the menstrual cycle. This may reflect the impact of knowledge or socio-cultural constructs, which impact individual perceptions of symptoms and their menstrual experience⁴⁴. Historically, menstruation has been mainly described negatively. Previous work has shown an association between early menstrual/menarchal experiences and current menstrual experience, body perception, and overall health^{45–48}. However, other studies examining symptom experience across broad geographic regions have not found regional differences in symptoms³⁹.

The strength of this study lies in the number of unique users and in a large amount of user-reported data from a global population. However, this study is not without limitations. Specifically, this study is subject to selection bias as not all menstruating individuals choose to use period tracking apps. Demographic and other individual characteristic data were not collected, including user-reported race and ethnicity, which may be important mediators of menstrual symptom characteristics and experiences that may impact our results. We included only ovulatory cycles with ovulation confirmed by self-ovulation test to more accurately divide the cycle into phases. Users logging ovulation tests likely have a goal of conception and may thus have a different experience of menstrual symptoms and a difference in the tendency of logging symptoms. Additionally, irregular and non-ovulatory cycles are not represented in this analysis, and results are not generalizable to these populations. Although this study represents a global menstruating population, many countries remain un- or underrepresented, presenting an

opportunity for future research. Other limitations include the use of self-reported symptom tracking data. Users log symptoms through the app but may not log symptoms consistently throughout the cycle (e.g. potentially more likely to log symptoms when logging other events such as ovulation or period) and may not log all symptoms experienced. Users also may be more likely to log symptoms that appear at the top and front of the app over symptoms that appear lower down or require scrolling to see, decreasing the representativeness of symptoms recorded and limiting comparability with other methods of symptom data collection.

In conclusion, our study presents an expanded understanding of symptoms experienced during the menstrual cycle. These findings reflect the value of population-level menstrual cycle data, which can help inform individual patients and clinicians while strengthening research efforts and calls for advocacy for Women's Health.

272 References

305

- 1. Lacovides S, Avidon I, Baker FC. What we know about primary dysmenorrhea today: a critical review. *Hum Reprod Update*. 2015;21(6):762-778. doi:10.1093/humupd/dmv039
- Moore J, Barlow D, Jewell D, Kennedy S. Do gastrointestinal symptoms vary with the menstrual cycle? *Br J Obstet Gynaecol*. 1998;105(12):1322-1325. doi:10.1111/j.1471-0528.1998.tb10014.x
- Judkins TC, Dennis-Wall JC, Sims SM, Colee J, Langkamp-Henken B. Stool frequency and form and gastrointestinal symptoms differ by day of the menstrual cycle in healthy adult women taking oral contraceptives: a prospective observational study. *BMC Womens Health*. 2020;20(1):136. doi:10.1186/s12905-020-01000-x
- 4. Lete I, Häusler G, Pintiaux A, et al. The inconvenience due to women's monthly bleeding
 (ISY) survey: a study of premenstrual symptoms among 5728 women in Europe. Eur J
 Contracept Reprod Health Care Off J Eur Soc Contracept. 2017;22(5):354-359.
 doi:10.1080/13625187.2017.1400001
- 5. Bernstein MT, Graff LA, Avery L, Palatnick C, Parnerowski K, Targownik LE.
 Gastrointestinal symptoms before and during menses in healthy women. *BMC Womens Health*. 2014;14:14. doi:10.1186/1472-6874-14-14
- Chen CX, Draucker CB, Carpenter JS. What women say about their dysmenorrhea: a
 qualitative thematic analysis. *BMC Womens Health*. 2018;18(1):47. doi:10.1186/s12905-018-0538-8
- 7. Chen CX, Kwekkeboom KL, Ward SE. Beliefs About Dysmenorrhea and Their Relationship to Self-Management. *Res Nurs Health*. 2016;39(4):263-276. doi:10.1002/nur.21726
- 8. Ramos-Pichardo JD, Ortega-Galán ÁM, Iglesias-López MT, Abreu-Sánchez A, Fernández-Martínez E. Why Do Some Spanish Nursing Students with Menstrual Pain Fail to Consult Healthcare Professionals? *Int J Environ Res Public Health*. 2020;17(21):E8173.
 doi:10.3390/ijerph17218173
- 9. Schoep ME, Adang EMM, Maas JWM, De Bie B, Aarts JWM, Nieboer TE. Productivity loss due to menstruation-related symptoms: a nationwide cross-sectional survey among 32 748 women. *BMJ Open*. 2019;9(6):e026186. doi:10.1136/bmjopen-2018-026186
- 301 10. Critchley HOD, Babayev E, Bulun SE, et al. Menstruation: science and society. *Am J Obstet Gynecol*. 2020;223(5):624-664. doi:10.1016/j.ajog.2020.06.004
- 303 11. Matteson KA, Zaluski KM. Menstrual Health as a Part of Preventive Health Care. *Obstet Gynecol Clin North Am.* 2019;46(3):441-453. doi:10.1016/j.ogc.2019.04.004
 - 12. Chen CX, Shieh C, Draucker CB, Carpenter JS. Reasons women do not seek health care for dysmenorrhea. *J Clin Nurs*. 2018;27(1-2):e301-e308. doi:10.1111/jocn.13946
- Tan DA, Haththotuwa R, Fraser IS. Cultural aspects and mythologies surrounding
 menstruation and abnormal uterine bleeding. *Best Pract Res Clin Obstet Gynaecol*.
 2017;40:121-133. doi:10.1016/j.bpobgyn.2016.09.015
- 310 14. Symul L, Wac K, Hillard P, Salathé M. Assessment of menstrual health status and
 311 evolution through mobile apps for fertility awareness. *NPJ Digit Med*. 2019;2:64.
 312 doi:10.1038/s41746-019-0139-4
- Mao L, Xi S, Bai W, et al. Menstrual patterns and disorders among Chinese women of reproductive age: A cross-sectional study based on mobile application data. *Medicine* (*Baltimore*). 2021;100(16):e25329. doi:10.1097/MD.0000000000025329
- 316 I6. Karasneh RA, Al-Azzam SI, Alzoubi KH, Muflih SM, Hawamdeh SS. Smartphone
 317 Applications for Period Tracking: Rating and Behavioral Change among Women Users.


- 318 *Obstet Gynecol Int.* 2020;2020:2192387. doi:10.1155/2020/2192387
- 319 17. Bull JR, Rowland SP, Scherwitzl EB, Scherwitzl R, Danielsson KG, Harper J. Real-320 world menstrual cycle characteristics of more than 600,000 menstrual cycles. *NPJ Digit Med*. 321 2019;2:83. doi:10.1038/s41746-019-0152-7
- 322 18. Mahalanobis P. On the generalised distance in statistics. *Proc Natl Inst Sci India*. 1936;2(1):49-55.
- 324 19. Leskovec J, Rajaraman A, Ullman JD. *Mining of Massive Data Sets*. Cambridge 325 University Press; 2020.
- 20. Li K, Urteaga I, Wiggins CH, et al. Characterizing physiological and symptomatic
 variation in menstrual cycles using self-tracked mobile-health data. *NPJ Digit Med*.
 2020;3:79. doi:10.1038/s41746-020-0269-8
- Najmabadi S, Schliep KC, Simonsen SE, Porucznik CA, Egger MJ, Stanford JB.
 Menstrual bleeding, cycle length, and follicular and luteal phase lengths in women without known subfertility: A pooled analysis of three cohorts. *Paediatr Perinat Epidemiol*.
 2020;34(3):318-327. doi:10.1111/ppe.12644
- Li K, Urteaga I, Shea A, Vitzthum VJ, Wiggins CH, Elhadad N. A predictive model for next cycle start date that accounts for adherence in menstrual self-tracking. *J Am Med Inform Assoc JAMIA*. 2021;29(1):3-11. doi:10.1093/jamia/ocab182
- 336 23. Grieger JA, Norman RJ. Menstrual Cycle Length and Patterns in a Global Cohort of
 337 Women Using a Mobile Phone App: Retrospective Cohort Study. *J Med Internet Res*.
 338 2020;22(6):e17109. doi:10.2196/17109
- 339 24. Broad A, Biswakarma R, Harper JC. A survey of women's experiences of using period tracker applications: Attitudes, ovulation prediction and how the accuracy of the app in predicting period start dates affects their feelings and behaviours. *Womens Health Lond Engl.* 2022;18:17455057221095246. doi:10.1177/17455057221095246
- 343 25. Graham JD, Clarke CL. Physiological action of progesterone in target tissues. *Endocr* 344 *Rev.* 1997;18(4):502-519. doi:10.1210/edrv.18.4.0308
- 345 26. Shechter A, Varin F, Boivin DB. Circadian variation of sleep during the follicular and luteal phases of the menstrual cycle. *Sleep*. 2010;33(5):647-656. doi:10.1093/sleep/33.5.647
- LeResche L, Mancl L, Sherman JJ, Gandara B, Dworkin SF. Changes in temporomandibular pain and other symptoms across the menstrual cycle. *Pain*.
 2003;106(3):253-261. doi:10.1016/j.pain.2003.06.001
- 350 28. Sacco S, Ricci S, Degan D, Carolei A. Migraine in women: the role of hormones and their impact on vascular diseases. *J Headache Pain*. 2012;13(3):177-189. doi:10.1007/s10194-012-0424-y
- Stening K, Eriksson O, Wahren L, Berg G, Hammar M, Blomqvist A. Pain sensations to the cold pressor test in normally menstruating women: comparison with men and relation to menstrual phase and serum sex steroid levels. *Am J Physiol Regul Integr Comp Physiol*.
 2007;293(4):R1711-1716. doi:10.1152/ajpregu.00127.2007
- 357 30. Raghunath RS, Venables ZC, Millington GWM. The menstrual cycle and the skin. *Clin Exp Dermatol*. 2015;40(2):111-115. doi:10.1111/ced.12588
- 359 31. Xiao ZL, Pricolo V, Biancani P, Behar J. Role of progesterone signaling in the regulation 360 of G-protein levels in female chronic constipation. *Gastroenterology*. 2005;128(3):667-675. 361 doi:10.1053/j.gastro.2004.12.001
- 362 32. Evans J, Salamonsen LA. Inflammation, leukocytes and menstruation. *Rev Endocr Metab* 2012;13(4):277-288. doi:10.1007/s11154-012-9223-7

- 364 33. Ryu A, Kim TH. Premenstrual syndrome: A mini review. *Maturitas*. 2015;82(4):436-365 440. doi:10.1016/j.maturitas.2015.08.010
- 36. Toffol E, Kalleinen N, Urrila AS, et al. The relationship between mood and sleep in different female reproductive states. *BMC Psychiatry*. 2014;14:177. doi:10.1186/1471-244X-14-177
- 35. Sanders D, Warner P, Bäckström T, Bancroft J. Mood, sexuality, hormones and the menstrual cycle. I. Changes in mood and physical state: description of subjects and method. *Psychosom Med.* 1983;45(6):487-501. doi:10.1097/00006842-198312000-00003
- 36. Meaden PM, Hartlage SA, Cook-Karr J. Timing and severity of symptoms associated with the menstrual cycle in a community-based sample in the Midwestern United States. *Psychiatry Res.* 2005;134(1):27-36. doi:10.1016/j.psychres.2005.01.003
- 375 37. Toffoletto S, Lanzenberger R, Gingnell M, Sundström-Poromaa I, Comasco E. Emotional
 376 and cognitive functional imaging of estrogen and progesterone effects in the female human
 377 brain: a systematic review. *Psychoneuroendocrinology*. 2014;50:28-52.
 378 doi:10.1016/j.psyneuen.2014.07.025
- 38. Sakaki M, Mather M. How reward and emotional stimuli induce different reactions across the menstrual cycle. *Soc Personal Psychol Compass*. 2012;6(1):1-17. doi:10.1111/j.1751-9004.2011.00415.x
- 39. Dennerstein L, Lehert P, Heinemann K. Global epidemiological study of variation of premenstrual symptoms with age and sociodemographic factors. *Menopause Int*. 2011;17(3):96-101. doi:10.1258/mi.2011.011028
- 385 40. Bertone-Johnson ER, Hankinson SE, Willett WC, Johnson SR, Manson JE. Adiposity 386 and the Development of Premenstrual Syndrome. *J Womens Health*. 2010;19(11):1955-1962. 387 doi:10.1089/jwh.2010.2128
- 388 41. Masho SW, Adera T, South-Paul J. Obesity as a risk factor for premenstrual syndrome. *J Psychosom Obstet Gynaecol.* 2005;26(1):33-39. doi:10.1080/01443610400023049
- 390 42. Sadler C, Smith H, Hammond J, et al. Lifestyle factors, hormonal contraceptives and
 391 premenstrual symptoms: The UK Southampton Women's Survey. *J Womens Health* 2002.
 392 2010;19(3):391-396. doi:10.1089/jwh.2008.1210
- 393 43. Kiesner J, Pastore M. Day-to-day co-variations of psychological and physical symptoms
 394 of the menstrual cycle: insights to individual differences in steroid reactivity.
 395 *Psychoneuroendocrinology*. 2010;35(3):350-363. doi:10.1016/j.psyneuen.2009.07.011
- 396 44. Marván ML, Escobedo C. Premenstrual symptomatology: role of prior knowledge about premenstrual syndrome. *Psychosom Med.* 1999;61(2):163-167. doi:10.1097/00006842-398 199903000-00007
- 45. McPherson ME, Korfine L. Menstruation across time: menarche, menstrual attitudes, experiences, and behaviors. *Womens Health Issues Off Publ Jacobs Inst Womens Health*. 2004;14(6):193-200. doi:10.1016/j.whi.2004.08.006
- 402 46. Stubbs ML. Cultural perceptions and practices around menarche and adolescent 403 menstruation in the United States. *Ann N Y Acad Sci*. 2008;1135:58-66. 404 doi:10.1196/annals.1429.008
- 47. Padmanabhanunni A, Jaffer L, Steenkamp J. Menstruation experiences of South African
 406 women belonging to the ama-Xhosa ethnic group. *Cult Health Sex.* 2018;20(6):704-714.
 407 doi:10.1080/13691058.2017.1371335
- 48. Barrington DJ, Robinson HJ, Wilson E, Hennegan J. Experiences of menstruation in high income countries: A systematic review, qualitative evidence synthesis and comparison to low-

and middle-income countries. *PloS One*. 2021;16(7):e0255001.

doi:10.1371/journal.pone.0255001

Figure 1. An illustrative description of cycle phases



Legend: Multiple sub-phases in the follicular phase of the menstrual cycle were used to more deeply assess symptoms during the menstrual cycle. The luteal phase was divided into two halves for the purpose of symptom report.

Figure 2: Number of unique cycles with experience of specific symptoms (n=498,126 cycles) and

percent of cycles with each symptom




Figure Legend: The number of unique cycles containing mood and somatic symptoms, group by type, are presented with a count of individual symptoms included in each category.

Figure 3: Symptom distribution by phase (n = 8,682,238 logged symptoms)




Figure Legend: Symptom distribution per phase of the menstrual cycle is shown. Y-axis represents the percentage of symptom occurrence and type of symptom reported.

Figure 4: Daily logs of the three symptoms within each category with the highest variability across the cycle for cycles between 25-30 days (n=294,180 cycles)




Figure 5 Proportion of users by country with experience of the top symptoms in each category during their last cycle (n=224,670 users with available country information)




Figure Legend: The prevalence of most frequently reported symptoms (Figure 5A cramps, Figure 5B bloating, Figure 5C mood swings) is showed by geographic distribution of app users.

Supplementary tables

Supplementary table 1. Users per country (in countries with at least 100 users), and prevalence of cramps, bloating, and mood swings.

Country	Number of users	Cramps	Bloating	Mood swings
Algeria	289	14.9	3.5	3.8
Angola	114	18.4	5.3	2.6
Argentina	776	12.8	8.9	4.1
Australia	7650	17.4	5.4	2.9
Austria	1669	17.9	5.0	3.4
Belarus	1021	21.5	4.3	4.2
Belgium	1356	19.1	4.8	3.3
Brazil	9804	15.5	4.3	4.9
Bulgaria	150	16.7	4.0	2.0
Cameroon	304	10.2	2.3	2.3
Canada	8802	18.3	5.1	2.3
Chile	390	13.6	8.7	2.8
China	568	10.9	4.6	5.5
Colombia	578	11.6	5.5	3.6
Congo	180	10.6	1.7	3.3
Costa Rica	112	10.7	4.5	7.1
Côte d'Ivoire	295	11.9	3.4	2.4
Croatia	173	16.2	2.3	2.3
Czech Republic	425	18.1	4.2	3.3
Denmark	1038	17.5	5.7	2.9
Dominican Republic	627	12.9	3.5	3.2
Ecuador	263	12.2	6.5	4.9
Egypt	191	11.5	4.7	5.8
Estonia	220	16.4	5.0	4.5

Finland	1663	18.9	4.9	1.9
France	8892	17.2	4.1	2.0
Germany	19956	17.4	4.9	2.9
Ghana	799	15.9	3.1	3.3
Greece	248	16.9	4.4	2.4
Guadeloupe	135	15.6	2.2	2.2
Guatemala	161	18.6	3.7	2.5
Honduras	128	20.3	7.0	2.3
Hong Kong	272	12.5	4.0	1.5
Hungary	220	20.9	5.0	1.8
Iceland	119	23.5	5.9	0.8
India	2054	15.8	4.4	4.1
Indonesia	1112	13.5	4.1	5.3
Ireland	1262	19.7	6.0	2.6
Israel	253	19.0	4.3	2.0
Italy	5739	14.4	4.0	3.6
Jamaica	367	12.0	3.8	7.6
Japan	1903	12.5	2.9	3.0
Kazakhstan	1138	16.2	5.9	5.5
Kenya	394	15.2	4.8	4.3
Korea	244	9.8	5.7	2.5
Latvia	153	17.6	7.2	3.9
Lebanon	115	14.8	2.6	0.9
Lithuania	145	20.7	4.1	3.4
Luxembourg	182	15.4	7.1	3.3
Malaysia	889	14.3	5.2	2.6
Mauritius	111	14.4	6.3	6.3
Mexico	2099	14.7	5.1	3.7
Morocco	144	16.0	5.6	3.5
Netherlands	2136	18.8	5.3	2.8
New Zealand	949	18.4	4.8	2.0

Nigeria	1739	13.5	3.5	5.8
Norway	1396	17.0	5.8	2.8
Pakistan	188	12.2	5.3	5.9
Panama	125	9.6	4.0	3.2
Paraguay	109	12.8	3.7	6.4
Peru	318	11.3	5.7	1.9
Philippines	1305	14.4	3.8	4.4
Poland	4145	12.5	2.9	3.9
Portugal	935	15.1	5.1	2.1
Puerto Rico	208	17.8	6.3	2.4
Réunion	133	16.5	4.5	1.5
Romania	493	18.7	6.7	2.8
Russian Federation	10984	20.0	4.4	3.8
Saudi Arabia	180	16.1	5.0	6.1
Senegal	123	15.4	3.3	3.3
Serbia	112	12.5	8.0	4.5
Singapore	910	16.7	4.6	1.6
Slovakia	112	13.4	7.1	2.7
Slovenia	146	15.1	6.2	2.7
South Africa	1697	16.6	5.2	3.6
Spain	3871	14.6	6.0	2.4
Sri Lanka	108	13.9	2.8	1.9
Sweden	3134	17.5	4.5	3.6
Switzerland	1526	17.4	4.1	2.2
Taiwan	408	9.8	3.7	2.2
Thailand	1018	9.5	1.9	3.7
Trinidad and Tobago	232	17.2	4.3	3.4
Tunisia	137	8.8	9.5	4.4
Turkey	654	13.8	6.7	3.4
Ukraine	1827	19.4	3.2	4.2
United Arab Emirates	450	15.8	5.8	1.8

United Kingdom	17437	18.2	5.2	2.6
United States	73015	19.0	5.3	2.6
Uzbekistan	137	9.5	5.8	3.6
Venezuela	293	9.9	4.1	4.1
Viet Nam	282	4.3	2.5	1.8
Zambia	163	13.5	6.7	3.1
Zimbabwe	104	14.4	4.8	1.9